Valsartan

Generic Name
Valsartan
Brand Names
Dafiro, Diovan, Diovan Hct, Entresto, Exforge, Exforge Hct
Drug Type
Small Molecule
Chemical Formula
C24H29N5O3
CAS Number
137862-53-4
Unique Ingredient Identifier
80M03YXJ7I
Background

Valsartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes telmisartan, candesartan, losartan, olmesartan, and irbesartan. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, which include vasoconstriction, stimulation and syn...

Indication

Valsartan is indicated for the treatment of hypertension to reduce the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. It is also indicated for the treatment of heart failure (NYHA class II-IV) and for left ventricular dysfunction or failure after myocardial infarction when the use of an angiotensin-converting ...

Associated Conditions
Cardiovascular Mortality, Diabetic Nephropathy, Heart Failure, Hypertension, Moderate Essential Hypertension, Chronic heart failure with reduced ejection fraction (NYHA Class II), Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV), Hospitalization due to cardiac failure
Associated Therapies
-
Clinical Trials
Related News

Assessment of LCZ696 and Valsartan in Asian Patients With Salt-sensitive Hypertension

Phase 2
Completed
Conditions
Salt-sensitive Hypertension
Interventions
Drug: Valsartan
Drug: LCZ696
First Posted Date
2012-09-10
Last Posted Date
2015-11-10
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
72
Registration Number
NCT01681576
Locations
🇨🇳

Novartis Investigative Site, Taipei, Taiwan

A Multicenter, Phase 3 Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan(BR-A-657∙K) 30mg Compared to Placebo in Patients With Mild to Moderate Essential Hypertension

Phase 3
Completed
Conditions
Hypertension
Interventions
Drug: Fimasartan
Drug: Placebo
Drug: Valsartan
First Posted Date
2012-08-27
Last Posted Date
2016-07-01
Lead Sponsor
Boryung Pharmaceutical Co., Ltd
Target Recruit Count
293
Registration Number
NCT01672476
Locations
🇰🇷

Severance Hospital, Seoul, Korea, Republic of

New Angiotensin II Receptor Blocker Azilsartan Study for Stronger Blood Pressure Lowering

Phase 4
Completed
Conditions
Hypertension
Interventions
Drug: Valsartan
Drug: Azilsartan
First Posted Date
2012-06-01
Last Posted Date
2013-10-30
Lead Sponsor
Nara Medical University
Target Recruit Count
70
Registration Number
NCT01609959
Locations
🇯🇵

First Department of Nara Medical University, Kashihara, Nara, Japan

Double-dose Valsartan Monotherapy in Hypertension Treatment: an Effectiveness and Safety Evaluation in Chinese Patients.

Phase 4
Completed
Conditions
Hypertension
Interventions
Drug: Valsartan
First Posted Date
2012-02-29
Last Posted Date
2017-03-21
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
200
Registration Number
NCT01541189
Locations
🇨🇳

Novartis Investigative Site, Beijing, Beijing, China

Controlled Release Nifedipine and Valsartan Combination Therapy in Patients With Essential Hypertension

First Posted Date
2012-01-26
Last Posted Date
2012-01-26
Lead Sponsor
Bayer
Target Recruit Count
514
Registration Number
NCT01518855

Effect of Valsartan on Left Ventricular Myocardial Functions in Hypertensive Patients With Left Ventricular Hypertrophy

Phase 4
Completed
Conditions
Hypertension
Left Ventricular Hypertrophy
Interventions
Drug: valsartan
First Posted Date
2011-08-30
Last Posted Date
2011-08-30
Lead Sponsor
Mustafa Kemal University
Target Recruit Count
38
Registration Number
NCT01425411
Locations
🇹🇷

Mustafa Kemal University School of Medicine, Department of Cardiology, Antioch, Turkey

Blood Pressure Lowering in Acute Stroke Trial

Phase 4
Withdrawn
Conditions
Stroke, Acute
First Posted Date
2011-07-22
Last Posted Date
2016-05-09
Lead Sponsor
Stanford University
Registration Number
NCT01400256
Locations
🇺🇸

Stanford University Medical Center, Stanford, California, United States

Safety and Tolerability of Valsartan in Children 6 to 17 Years of Age

First Posted Date
2011-06-03
Last Posted Date
2016-07-13
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
150
Registration Number
NCT01365481
Locations
🇸🇬

Novartis Investigative Site, Singapore, Singapore

Sodium Excretion of LCZ696 in Patients With Hypertension; Heart Failure and Healthy Volunteers

Phase 2
Completed
Conditions
Hypertension
Interventions
Drug: LCZ696
Drug: Valsartan
First Posted Date
2011-05-13
Last Posted Date
2015-11-23
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
32
Registration Number
NCT01353508
Locations
🇷🇺

Novartis Investigative Site, Moscow, Russian Federation

An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension

First Posted Date
2011-01-21
Last Posted Date
2016-01-29
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
910
Registration Number
NCT01281306
Locations
🇪🇸

Novartis Investigative Site, Madrid, Spain

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy